Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 718

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 4
Chunk 718
---
 merchant bank &
private equity firm focused on the “green” economy. From 2015 through 2018, Mr. Vassily served as an Associate Director
of Research at Keybanc Capital Markets, and helped to co-manage the technology research vertical. From 2010 to 2014, he served as the
Director of Research at Pacific Epoch, where he was responsible for a complete product overhaul and a complete business model restart
post- acquisition, re-focusing the firm around a “data-first” research offering. From 2007 to 2010, he served as the Asia
Technology Business Development Representative and as a Senior Analyst at Pacific Crest Securities. In this role, he was responsible for
establishing the firm’s presence and relevance covering Asia Technology. From 2003 to 2006, he served as a Senior Research Analyst
in the semiconductor technology group at Susquehanna International Group, where he was responsible for research in semiconductor and related
technologies. From 2001 to 2003, Mr. Vassily served as a Vice President and Senior Research Analyst for semiconductor capital equipment
at Thomas Weisel Partners, where he was responsible for publishing research and maintaining financial models on each of the companies
under coverage. Mr. Vassily began his career on Wall Street in 1998 as a Research Associate covering the semiconductor industry at
Lehman Brothers. Mr. Vassily earned a B.A. degree from Denison University and an MBA from Dartmouth College, Tuck School of Business.

Number
and Terms of Office of Officers and Directors

Our
board of directors consists of three members. Holders of our founder shares will have the right to elect all of our directors prior to
consummation of our initial business combination and holders of our public shares will not have the right to vote on the appointment
of directors during such time. These provisions of our amended and restated memorandum and articles of association may only be amended
if approved by holders of at least 90% of our issued and outstanding ordinary shares entitled to vote thereon. Each of our directors
will hold office for a two-year term. Subject to any other special rights applicable to the shareholders, any vacancies on our board
of directors may be filled by the affirmative vote of a majority of the remaining directors of our board or by a majority of the holders
of our ordinary shares (or, prior to our initial business combination, a majority of the holders of our founder